121 related articles for article (PubMed ID: 38430041)
1. Correlation between PD-1 and sPD-L1 expression levels in peripheral blood of DLBCL patients and their clinicopathological characteristics.
Wang L; Cao C; Qiu J; Zhang J; He Q; Song L; Xie L; Ma J
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):44-50. PubMed ID: 38430041
[TBL] [Abstract][Full Text] [Related]
2. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
3. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.
Fang X; Xiu B; Yang Z; Qiu W; Zhang L; Zhang S; Wu Y; Zhu X; Chen X; Xie S; Yi X; Liang A; Zeng Y
Medicine (Baltimore); 2017 Apr; 96(15):e6398. PubMed ID: 28403071
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors.
Ibrahim EM; Refat S; El-Ashwah S; Fahmi MW; Ibrahiem AT
J Egypt Natl Canc Inst; 2023 May; 35(1):12. PubMed ID: 37150782
[TBL] [Abstract][Full Text] [Related]
5. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
6. [Levels and Clinical Significances of sPD-1 and sPD-L1 in Peripheral Blood of Lymphoma Patients].
Liu XL; He P; Lei J; Zou LX; Peng L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1733-1738. PubMed ID: 38071053
[TBL] [Abstract][Full Text] [Related]
7. Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin's lymphoma.
Feng X; Luo X; Yang Y; Fan Y; Ye Q
Medicine (Baltimore); 2023 Nov; 102(44):e35757. PubMed ID: 37933048
[TBL] [Abstract][Full Text] [Related]
8. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
[TBL] [Abstract][Full Text] [Related]
9. Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients.
El-Ghammaz AMS; Gadallah HA; Kamal G; Maher MM; Mohamad MA
Clin Exp Med; 2018 Nov; 18(4):505-512. PubMed ID: 29876769
[TBL] [Abstract][Full Text] [Related]
10. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
11. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
12. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
He J; Pan Y; Guo Y; Li B; Tang Y
J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified.
Slak TC; Miceska S; Gasljevic G; Boltezar L; Kloboves-Prevodnik V
Radiol Oncol; 2024 Mar; 58(1):99-109. PubMed ID: 38378036
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
[TBL] [Abstract][Full Text] [Related]
16. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
17. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
[TBL] [Abstract][Full Text] [Related]
18. Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.
Zhang J; Zhang H; Luo Y
Med Sci Monit; 2019 Feb; 25():1275-1282. PubMed ID: 30771277
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis.
Al-Khateeb E; Abbas MA; Khader MB; Sughayer MA
Int J Biol Markers; 2023 Mar; 38(1):53-60. PubMed ID: 36617986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]